首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1871509

2021-2031年亚太地区人类微生物组市场报告：范围、细分、动态和竞争分析

Asia Pacific Human Microbiome Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

出版日期: 2025年09月01日 | 出版商:

The Insight Partners | 英文 138 Pages | 订单完成后即时交付

价格

简介目录图表

预计亚太地区人类微生物组市场将显着成长，到 2031 年将达到约 7.0384 亿美元，高于 2023 年的 1.241 亿美元，在此期间复合年复合成长率(CAGR) 将达到 24.2%。

执行摘要和市场分析

市场分为多个区域，包括澳洲、中国、印度、日本、韩国以及亚太其他地区。推动该市场成长的关键因素包括代谢紊乱盛行率的上升、基因突变研究和药物开发需求的增加，以及市场参与者之间的策略合作。此外，旨在提高公众对人类微生物组认识的政府措施和资金投入也进一步推动了市场扩张。

市场区隔

亚太地区人类微生物组市场可以透过类型、应用和疾病类型等多个细分市场进行分析。

类型：市场分为产品和软体/服务两大类，其中产品类在 2023 年占据主导地位。该类市场可进一步细分为益生菌和益生元。
应用领域：市场分为治疗、诊断和研究三个部分，其中治疗领域在 2023 年占据最大的市场份额。
疾病类型：市场也按疾病类型细分，包括肥胖症、糖尿病、自体免疫疾病、癌症、胃肠道 (GIT) 问题等，其中 GIT 细分市场在 2023 年占据市场份额领先地位。

市场展望

人类微生物组在医疗保健领域具有革命性变革的潜力，这促使相关研发投资激增。微生物组由数兆栖息于人体内外的微生物组成，在维持健康和预防疾病方面发挥着至关重要的作用。生技新创公司和製药公司正加大对以微生物组为基础的疗法研发的投入。例如，印度领先的微生物组新创公司之一Xome Life Sciences，致力于开发利用微生物组资料改善健康状况的诊断和治疗工具。

此外，Seres Therapeutics公司针对復发性艰难梭菌感染的治疗方案已获得FDA批准，展现了基于微生物组的药物的巨大治疗潜力。像Vedanta Biosciences这样的公司也在筹集大量资金，用于开发源自微生物组的免疫疗法，以治疗自体免疫疾病和癌症等疾病。包括Seventure Partners和Flagship Pioneering在内的知名投资者正在积极支持分析微生物组资料的公司，这凸显了人们对微生物组在健康领域重要性的日益重视。预计这股投资热潮将推动精准医疗和治疗介入的进步，并在市场中创造众多机会。

国家概况

亚太地区人类微生物组市场涵盖中国、日本、印度、澳洲、韩国等主要国家，其中中国在2023年占据最大的市场份额。新药研发、产品改进和策略合作等因素显着推动了中国微生物组疗法市场的发展。例如，人工智慧驱动的微生物组疗法公司Xbiome Inc.收购了Assembly Biosciences的一个临床阶段项目，该项目专注于开发针对乙型肝炎等病毒性疾病的创新疗法。

目标疾病盛行率的不断上升预计将进一步刺激人类微生物组市场的成长。研究不断揭示微生物组在多种健康状况中的关键作用，从而引发了人们对基于微生物组的疗法的浓厚兴趣，尤其是在胃肠道疾病、自体免疫疾病和代谢性疾病方面。微生物组疗法有望提供更有效、更个人化的治疗方案，这为市场成长开闢了广阔前景。根据美国国立卫生研究院（NIH）的数据显示，中国肠躁症（IBS）的盛行率在2.3%至15.8%之间，显示该领域存在巨大的市场机会。

公司简介

人类微生物组市场的主要参与者包括 MaaT Pharma、Ferring Holdings SA、AOBiome Therapeutics Inc、Finch Therapeutics Group Inc、Seres Therapeutics Inc、Merck & Co Inc、Rebiotix, Inc.、Yakult Honsha Co., Ltd.、IFF Nutrition & Biosciences 和 Synthetic Biologics, Inc.。这些公司正在采用各种策略，包括扩张、产品创新以及併购，以增强其产品供应并提高市场份额。

The market is divided into several regions, including Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Key drivers of growth in this market include the rising prevalence of metabolic disorders, an increasing demand for research in gene mutation and drug development, and strategic collaborations among market participants. Additionally, government initiatives and funding aimed at enhancing awareness of the human microbiome are further propelling market expansion.

Market Segmentation

The Asia Pacific human microbiome market can be analyzed through various segments, including type, application, and disease type.

Type: The market is categorized into products and software/services, with the product segment dominating in 2023. This segment is further divided into probiotics and prebiotics.
Application: The market is segmented into therapeutics, diagnostics, and research, with therapeutics holding the largest market share in 2023.
Disease Type: The market is also segmented by disease type, including obesity, diabetes, autoimmune disorders, cancer, gastrointestinal (GIT) issues, and others, with the GIT segment leading in market share in 2023.

Market Outlook

The human microbiome's potential to revolutionize healthcare has led to a surge in investments in research and development. The microbiome, consisting of trillions of microorganisms residing in and on the human body, plays a crucial role in maintaining health and preventing diseases. Biotech startups and pharmaceutical companies are increasingly funding the development of microbiome-based therapies. For instance, Xome Life Sciences, one of India's pioneering microbiome startups, is focused on creating diagnostic and therapeutic tools that leverage microbiome data to enhance health outcomes.

Moreover, Seres Therapeutics has received FDA approval for a treatment targeting recurrent Clostridium difficile infections, showcasing the therapeutic potential of microbiome-based drugs. Companies like Vedanta Biosciences are also raising significant funds to develop immunotherapies derived from microbiomes for conditions such as autoimmune disorders and cancer. Notable investors, including Seventure Partners and Flagship Pioneering, are actively supporting companies that analyze microbiome data, highlighting the growing recognition of the microbiome's importance in health. This influx of investment is expected to drive advancements in precision medicine and therapeutic interventions, creating numerous opportunities within the market.

Country Insights

The Asia Pacific human microbiome market includes key countries such as China, Japan, India, Australia, South Korea, and others, with China holding the largest market share in 2023. Factors such as new pharmaceutical developments, product enhancements, and strategic partnerships are significantly benefiting the microbiome therapies market in China. For example, Xbiome Inc., an AI-driven microbiome therapeutics company, has acquired a clinical-stage program from Assembly Biosciences, which is focused on innovative treatments for viral disorders like hepatitis B.

The increasing prevalence of target disorders is expected to further stimulate growth in the human microbiome market. Research continues to uncover the microbiome's critical role in various health conditions, leading to a heightened interest in microbiome-based therapies, particularly for gastrointestinal disorders, autoimmune diseases, and metabolic disorders. The potential for microbiome therapeutics to offer more effective and personalized treatment options presents a promising avenue for market growth. According to the National Institute of Health, the prevalence of Irritable Bowel Syndrome (IBS) in China ranges from 2.3% to 15.8%, indicating a significant market opportunity.

Company Profiles

Key players in the human microbiome market include MaaT Pharma, Ferring Holdings SA, AOBiome Therapeutics Inc, Finch Therapeutics Group Inc, Seres Therapeutics Inc, Merck & Co Inc, Rebiotix, Inc., Yakult Honsha Co., Ltd., IFF Nutrition & Biosciences, and Synthetic Biologics, Inc. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their product offerings and increase market share.

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. Asia Pacific Human Microbiome Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Significant Investments by Key Market Players
- 4.1.2 Government Initiatives
4.2 Market Restraints
- 4.2.1 Challenges During Production of Microbiome
4.3 Market Opportunities
- 4.3.1 Robust Investment in Research and Development
4.4 Future Trends
- 4.4.1 Emergence of Precision Medicine
4.5 Impact of Drivers and Restraints:

5. Human Microbiome Market - Asia Pacific Analysis

5.1 Asia Pacific Human Microbiome Market Revenue (US$ Million), 2021-2031
5.2 Asia Pacific Human Microbiome Market Forecast Analysis

6. Asia Pacific Human Microbiome Market Analysis - by Type

6.1 Product
- 6.1.1 Overview
- 6.1.2 Product: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.2 Software and Services
- 6.2.1 Overview
- 6.2.2 Software and Services: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Asia Pacific Human Microbiome Market Analysis - by Application

7.1 Therapeutics
- 7.1.1 Overview
- 7.1.2 Therapeutics: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Diagnostics
- 7.2.1 Overview
- 7.2.2 Diagnostics: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Research
- 7.3.1 Overview
- 7.3.2 Research: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Asia Pacific Human Microbiome Market Analysis - by Disease Type

8.1 Obesity
- 8.1.1 Overview
- 8.1.2 Obesity: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Diabetes
- 8.2.1 Overview
- 8.2.2 Diabetes: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Autoimmune Disorder
- 8.3.1 Overview
- 8.3.2 Autoimmune Disorder: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Cancer
- 8.4.1 Overview
- 8.4.2 Cancer: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.5 GIT
- 8.5.1 Overview
- 8.5.2 GIT: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Asia Pacific Human Microbiome Market - Country Analysis

9.1 Asia Pacific
- 9.1.1 Asia Pacific Human Microbiome Market Overview
- 9.1.2 Asia Pacific Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 9.1.2.1 Asia Pacific Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 9.1.2.2 China: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.2.1 China: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.2.2 China: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.2.3 China: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.2.4 China: Asia Pacific Human Microbiome Market Share - by Disease Type
  - 9.1.2.3 Japan: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.3.1 Japan: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.3.2 Japan: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.3.3 Japan: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.3.4 Japan: Asia Pacific Human Microbiome Market Share - by Disease Type
  - 9.1.2.4 India: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.4.1 India: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.4.2 India: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.4.3 India: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.4.4 India: Asia Pacific Human Microbiome Market Share - by Disease Type
  - 9.1.2.5 Australia: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.5.1 Australia: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.5.2 Australia: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.5.3 Australia: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.5.4 Australia: Asia Pacific Human Microbiome Market Share - by Disease Type
  - 9.1.2.6 South Korea: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.6.1 South Korea: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.6.2 South Korea: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.6.3 South Korea: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.6.4 South Korea: Asia Pacific Human Microbiome Market Share - by Disease Type
  - 9.1.2.7 Rest of APAC: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.7.1 Rest of APAC: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.7.2 Rest of APAC: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.7.3 Rest of APAC: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.7.4 Rest of APAC: Asia Pacific Human Microbiome Market Share - by Disease Type

10. Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Human Microbiome Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 MaaT Pharma
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Ferring Holdings SA
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 AOBiome Therapeutics Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Finch Therapeutics Group Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Financial Overview
- 11.4.4 SWOT Analysis
- 11.4.5 Key Developments
11.5 Seres Therapeutics Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Merck & Co Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Yakult Honsha Co., Ltd.
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Rebiotix, Inc.
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 IFF Nutrition & Biosciences
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 Synthetic Biologics, Inc.
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 Glossary of Terms
12.2 About The Insight Partners

简介目录图表

List Of Tables

Table 1. Asia Pacific Human Microbiome Market Segmentation
Table 2. Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Table 3. Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Type
Table 4. Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Application
Table 5. Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Disease Type
Table 6. Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
Table 7. China: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 8. China: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 9. China: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 10. China: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 11. Japan: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 12. Japan: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 13. Japan: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 14. Japan: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 15. India: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 16. India: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 17. India: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 18. India: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 19. Australia: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 20. Australia: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 21. Australia: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 22. Australia: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 23. South Korea: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 24. South Korea: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 25. South Korea: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 26. South Korea: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 27. Rest of APAC: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 28. Rest of APAC: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 29. Rest of APAC: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 30. Rest of APAC: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 31. Recent Organic Growth Strategies in the Human Microbiome Market
Table 32. Recent Inorganic Growth Strategies in the Human Microbiome Market
Table 33. Glossary of Terms, Human Microbiome Market

List Of Figures

Figure 1. Asia Pacific Human Microbiome Market Segmentation - Country
Figure 2. Asia Pacific Human Microbiome Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Human Microbiome Market Revenue (US$ Million), 2021-2031
Figure 5. Asia Pacific Human Microbiome Market Share (%) - by Type (2023 and 2031)
Figure 6. Product: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 7. Software and Services: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 8. Asia Pacific Human Microbiome Market Share (%) - by Application (2023 and 2031)
Figure 9. Therapeutics: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 10. Diagnostics: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 11. Research: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 12. Asia Pacific Human Microbiome Market Share (%) - by Disease Type (2023 and 2031)
Figure 13. Obesity: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 14. Diabetes: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 15. Autoimmune Disorder: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 16. Cancer: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 17. GIT: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 18. Others: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 19. Asia Pacific Human Microbiome Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 20. China: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 21. Japan: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 22. India: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 23. Australia: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 24. South Korea: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 25. Rest of APAC: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 26. Growth Strategies in the Human Microbiome Market